BNB Plus Corp. (Nasdaq: BNBX) announced that it has received a $1.2 million order for its LineaDNA product from a global manufacturer of in vitro diagnostics under an existing supply agreement. This order consolidates a previously planned two-year purchasing cycle into an accelerated delivery schedule, with completion expected by May 2026. Including this order, the company expects to ship over $1.5 million of LineaDNA to customers in the in vitro diagnostics and biotherapeutic markets in the first half of 2026. The company also recently completed the manufacture and shipment of a LineaDNA order valued at over $390,000.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BNB Plus Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260105461599) on January 05, 2026, and is solely responsible for the information contained therein.
Comments